[A20-98] Niraparib (first-line maintenance treatment in advanced ovarian cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 01.03.2021
Commission awarded on 26.11.2020 by the Federal Joint Committee (G-BA).
Adult patients with advanced epithelial (FIGO stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A19-88||Niraparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|G17-15||Niraparib (ovarian cancer) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V||Commission completed|
|A21-17||Niraparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|